Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule | 24 Oct 2024 |
| Orion publishes Interim Report for January-September 2024 and holds a webcast on 29 October 2024 | 15 Oct 2024 |
| Orion's collaboration partner Bayer submits application for third indication of darolutamide in the EU | 14 Oct 2024 |
| Orion's near-term climate targets approved by the Science Based Targets initiative | 30 Sept 2024 |
| Orion's collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster | 26 Sept 2024 |